SELLAS Life Sciences Group, Inc. (SLS)
11.54
-1.94
(-14.42%)
USD |
NASDAQ |
Sep 11, 16:00
11.56
+0.02
(+0.13%)
After-Hours: 20:00
SELLAS Life Sciences Group Enterprise Value : 2.193B for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 2.193B |
| September 10, 2026 | 2.586B |
| September 09, 2026 | 2.679B |
| September 08, 2026 | 2.681B |
| September 04, 2026 | 2.661B |
| September 03, 2026 | 2.629B |
| September 02, 2026 | 2.721B |
| September 01, 2026 | 2.532B |
| August 31, 2026 | 2.556B |
| August 28, 2026 | 2.530B |
| August 27, 2026 | 2.933B |
| August 26, 2026 | 2.635B |
| August 25, 2026 | 2.707B |
| August 24, 2026 | 2.755B |
| August 21, 2026 | 2.984B |
| August 20, 2026 | 2.568B |
| August 19, 2026 | 2.659B |
| August 18, 2026 | 2.507B |
| August 17, 2026 | 2.487B |
| August 14, 2026 | 2.443B |
| August 13, 2026 | 2.358B |
| August 12, 2026 | 2.239B |
| August 11, 2026 | 2.093B |
| August 10, 2026 | 2.091B |
| August 07, 2026 | 2.287B |
| Date | Value |
|---|---|
| August 06, 2026 | 2.225B |
| August 05, 2026 | 2.257B |
| August 04, 2026 | 2.247B |
| August 03, 2026 | 2.128B |
| July 31, 2026 | 1.884B |
| July 30, 2026 | 1.940B |
| July 29, 2026 | 1.902B |
| July 28, 2026 | 1.900B |
| July 27, 2026 | 2.050B |
| July 24, 2026 | 2.148B |
| July 23, 2026 | 2.354B |
| July 22, 2026 | 2.301B |
| July 21, 2026 | 2.467B |
| July 20, 2026 | 2.381B |
| July 17, 2026 | 2.526B |
| July 16, 2026 | 2.235B |
| July 15, 2026 | 2.445B |
| July 14, 2026 | 2.566B |
| July 13, 2026 | 2.411B |
| July 10, 2026 | 2.439B |
| July 09, 2026 | 2.590B |
| July 08, 2026 | 2.641B |
| July 07, 2026 | 2.588B |
| July 06, 2026 | 2.677B |
| July 02, 2026 | 2.887B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Lite Strategy, Inc. | 31.48M |
| AbbVie, Inc. | 518.65B |
| Marker Therapeutics, Inc. | 7.252M |
| TG Therapeutics, Inc. | 8.452B |
| Rezolute, Inc. | 287.20M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -9.605M |
| Total Expenses (Quarterly) | 9.605M |
| EPS Diluted (Quarterly) | -0.0508 |
| Earnings Yield | -1.84% |
| Normalized Earnings Yield | -1.838 |